Cardiac Marker Testing
Cardiac Marker Testing Market by Product (Instruments, Reagents & Kits), Biomarker (BNP Or NT-ProBNP, Ceratine Kinase-MB, hs-CRP), Type of Testing, Disease - Global Forecast 2024-2030
360iResearch Analyst
Want to know more about the cardiac marker testing market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[182 Pages Report] The Cardiac Marker Testing Market size was estimated at USD 5.10 billion in 2023 and expected to reach USD 5.50 billion in 2024, at a CAGR 7.90% to reach USD 8.69 billion by 2030.

Cardiac marker testing market consists of the spectrum of medical technologies and services that revolve around the usage of biomarkers for the diagnosis and management of cardiovascular diseases. The prevalence of cardiovascular diseases and need for effective diagnostics has increased the adoption of cardiac markers worldwide. The rise of point-of-care testing for cardiac markers has significantly increased the screening of cardiovascular diseases. The initiatives encouraging early cardiovascular disease detection have also contributed to market growth. However, the incidences of product recalls of cardiac marker testing solutions may limit its market adoption. The concerns associated with inaccuracy and limited specificity of cardiac market testing are also challenging factors for the market growth. Moreover, the advancements in testing technologies and the integration of new biomarkers are creating attractive opportunities in the market. Increasing consumer preference towards personalized medicine and the introduction of tailored cardiac marker testing are expected to witness significant growth in upcoming years.

Regional Insights

In the Americas region, the cardiac marker testing market has been flourishing with advancements in technology and the escalating prevalence of cardiovascular diseases. Several local companies and start-ups in major countries such as the United States, Canada, and Brazil, have been focusing on developing and introducing cost-effective and portable devices for effective cardiac assessment. In the Europe region, the cardiac marker testing market has been extensively driven by the increasing number of cardiovascular diseases, the aging population, and the well-established healthcare infrastructure. The cardiac marker testing market in the Middle East and Africa has been significantly impacted due to the rising awareness about coronary people diseases and the expansion of healthcare services. Cardiac marker testing market has been growing at an accelerated rate in APAC countries including China, India, and Japan due to the surge in healthcare services and the significant presence of major companies. The government support in terms of investments for healthcare research and development has led to an increase in innovations in cardiac testing methods.

Cardiac Marker Testing Market
To learn more about this report, request a free PDF copy
Market Dynamics

The market dynamics represent an ever-changing landscape of the Cardiac Marker Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Prevalence of cardiovascular diseases and need for effective diagnostics
    • Rise of point-of-care testing for cardiac markers worldwide
    • Initiatives encouraging early detection and screening of cardiovascular diseases
  • Market Restraints
    • Adverse recalls of cardiac marker testing products
  • Market Opportunities
    • Advancements in testing technologies and integration of new biomarkers
    • Shift toward personalized medicine and introduction of tailored cardiac marker testing
  • Market Challenges
    • Concerns associated with inaccuracy and limited specificity of cardiac marker testing
Market Segmentation Analysis
  • Product: Significance of diagnostic instruments in cardiac marker testing

    Diagnostic instruments in cardiac marker testing includes immunoassay analyzers, point of care (POC) devices, and chemiluminescence analyzers utilized to monitor and measure cardiac markers corresponding to heart conditions. Diagnostic instruments offer essential data evaluation for cardiac tests in a highly accurate, timely, and user-friendly manner. Reagents & kits are chemical solutions used for the proper functioning of instruments and the successful execution of cardiac marker testing procedures. Reagents & kits are vital in reacting with the biological samples, thereby helping to detect cardiac markers for various cardiac conditions.

  • Biomarker: Rising utilization of Troponin biomarker for cardiac assessment

    Natriuretic peptides such as N-terminal proBNP (NT-proBNP) and B-type Natriuretic Peptide (BNP) are essential in the evaluation of heart failure, helping clinicians on cardiac disease management. Though CK-MB, a Creatine Kinase-MB isoenzyme, has been used in periprocedural myocardial infarction testings to better diagnose cardiac condition. High-sensitivity C-reactive protein (hs-CRP) testing is particularly advantageous for identifying low-grade inflammation to assess the risk of cardiovascular disease and stroke. Myoglobin is also a significant cardiac biomarker, favored for its very early peak (1 to 3 hours) following myocardial injury, primarily beneficial in the early detection of myocardial infarction. Troponin tests are currently the standard of care for diagnosing acute myocardial infarction due to their superior sensitivity and specificity.

  • Type of Testing: Increasing adoption of Point-of-Care testing

    Laboratory testing involves analyzing patient samples in controlled lab environments, usually within hospitals or diagnostic centers, and utilizes advanced equipment for utmost accuracy. The high sensitivity and specificity of cardiac marker tests make it the preferred choice when precise results are mandatory in laboratory settings. Point-of-Care Testing (POCT) delivers rapid results in close proximity to the patient's location and are crucial in emergency cardiac conditions, facilitating real-time, actionable decisions that can significantly impact patient outcomes in cardiac disease conditions.

  • Disease: Extensive applications of cardiac marker testing in myocardial infarction

    B-type Natriuretic Peptide (BNP) and N-terminal pro b-type Natriuretic Peptide (NT-proBNP) testing are used as primary cardiac marker tests for congestive heart failure due to their ability to prompt and accurate detection of symptoms. Myocardial infarction condition is effectively analyzed by cardiac marker tests such as troponin tests as troponin T and I levels in the blood increases after heart muscle damage.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Cardiac Marker Testing Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Cardiac Marker Testing Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cardiac Marker Testing Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Cardiac Marker Testing Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Cardiac Marker Testing Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Cardiac Marker Testing Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Cardiac Marker Testing Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Cardiac Marker Testing Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Cardiac Marker Testing Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Cardiac Marker Testing Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Marker Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Marker Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays

    Mindray, a provider of medical devices and solutions, launched two advanced cardiac biomarkers, high-sensitivity troponin I (hs-cTnI) and NT-proBNP, for diagnosing and managing cardiovascular diseases (CVDs). The NT-proBNP assay demonstrates exceptional precision, with a coefficient of variation (CV) of less than or equal to 5%. Furthermore, it eliminates interference from 55 medications commonly used to treat heart diseases. This makes it a highly reliable tool for detecting and managing heart failure. Mindray's commitment to innovation in cardiac marker testing ensures accurate and efficient diagnosis and management of CVDs. [Published On: 2023-10-23]

  • NOWDx and AeenaDx Announce Merger

    NOWDx and AeenaDx have merged to form NOWDiagnostics (NOWDx). NOWDx is strategically positioned to cater to the global point of care (POC) and over-the-counter (OTC) diagnostics market. The main areas of focus for NOWDx include the commercialization of tests for Syphilis and Strep, as well as ongoing development for infectious diseases, women's health, drugs of abuse, cardiac markers, and cancer. The company is committed to delivering accurate and reliable diagnostic solutions to healthcare providers and patients worldwide. [Published On: 2023-04-28]

  • Pathkind Labs, Roche Diagnostics Partner to Release Cardiac Biomarker

    Pathkind Labs and Roche Diagnostics are partnered to introduce NTProBNP, a cardiac marker used for detecting heart failure in patients. Research conducted by the Trivandrum Heart-Failure Registry demonstrates that T2DM is a common comorbidity among hospitalized patients, accounting for 55 percent of cases. This marker is crucial in managing Type 2 Diabetes (T2DM) while re-evaluating the patient's treatment. [Published On: 2023-01-06]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Marker Testing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Marker Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Assure Tech (Hangzhou) Co., Ltd., Atlas Medical GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biomérieux SA, Boditech Med Inc., Charles River Laboratories International, Inc., Cleerly, Inc., Danaher Corporation, DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffmann-La Roche AG, HyTest Ltd., Laboratory Corporation of America Holdings, LightDeck Diagnostics, Merck KGaA, Natera, Inc., PerkinElmer Inc., Qiagen N.V., Quest Diagnostics, QuidelOrtho Corporation, Randox Laboratories Ltd., Sekbio, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Corporation.

Cardiac Marker Testing Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Cardiac Marker Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Instruments
      • Chemiluminescence
      • ELISA
      • Immunochromatography
      • Immunofluorescence
    • Reagents & Kits
  • Biomarker
    • BNP Or NT-ProBNP
    • Ceratine Kinase-MB
    • hs-CRP
    • Myoglobin
    • Troponin
  • Type of Testing
    • Laboratory Testing
    • Point-Of-Care Testing
  • Disease
    • Congestive Heart Failure
    • Myocardial Infarction

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Cardiac Marker Testing Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Cardiac Marker Testing Market, by Product
  7. Cardiac Marker Testing Market, by Biomarker
  8. Cardiac Marker Testing Market, by Type of Testing
  9. Cardiac Marker Testing Market, by Disease
  10. Americas Cardiac Marker Testing Market
  11. Asia-Pacific Cardiac Marker Testing Market
  12. Europe, Middle East & Africa Cardiac Marker Testing Market
  13. Competitive Landscape
  14. Competitive Portfolio
  15. List of Figures [Total: 24]
  16. List of Tables [Total: 466]
  17. List of Companies Mentioned [Total: 30]
The Growing Importance of Point-of-Care Testing for Cardiac Markers Worldwide
November 30, 2023
The Growing Importance of Point-of-Care Testing for Cardiac Markers Worldwide
Cardiovascular diseases are the leading cause of mortality rate worldwide, accounting for almost one-third of all demises. Rapid diagnosis and early management are critical for improving patient outcomes. In recent years, the adoption of point-of-care (POC) testing has surged due to its ability to provide fast, accurate, and reliable results. This trend has also impacted cardiac marker testing, which has become an integral part of cardiovascular diagnostics and management. In this blog post, we’ll explore the rise of POC testing for cardiac markers and its growing importance worldwide.

First, let's briefly understand what cardiac markers are. Cardiac markers are substances found in the blood that indicate the presence of heart damage or disease. Cardiac marker testing measures these substances to help diagnose, assess, and manage various cardiovascular conditions. Common cardiac markers include troponin, creatine kinase (CK), myoglobin, and brain natriuretic peptide (BNP).

Traditionally, cardiac marker testing is performed in hospital and clinical laboratories, requiring time-consuming procedures and skilled personnel. However, with the advancement of POC testing, healthcare providers can now obtain test results rapidly and easily at the patient's bedside. POC testing for cardiac markers is done using handheld devices that deliver accurate results with high sensitivity and specificity.

The adoption of POC testing for cardiac markers is on the rise for several reasons. First, it enables fast decision-making and management of cardiac patients, improving patient outcomes considerably. Secondly, POC testing reduces turnaround time and delays in treatment, resulting in increased hospital efficiency. Thirdly, POC testing saves costs associated with laboratory testing, staffing, and equipment maintenance, making it a cost-effective option for healthcare providers. There is a growing demand for POC testing due to the burden of cardiovascular diseases and the need for affordable diagnostics. Several companies are already introducing POC testing devices specifically designed for low-resource settings in such countries.

POC testing for cardiac markers has also been beneficial for remote and rural settings, where access to hospital facilities can be a challenge. Here, POC testing has enabled rapid diagnosis and treatment of cardiac patients, preventing complications and reducing mortality rates. Portable POC devices have been developed that can be transported to remote areas with ease, ensuring timely diagnosis and management of cardiac patients, even in the most challenging of circumstances.

The advent of point-of-care testing for cardiac marker testing has revolutionized cardiovascular diagnostics and management worldwide. The convenience, accuracy, and speed of POC testing have made it an integral part of cardiovascular care worldwide. It has not only improved clinical outcomes but has also been instrumental in reducing healthcare costs and increasing hospital efficiency. We can look forward to more advances in POC testing for cardiac markers as technology continues to advance, enabling us to provide better care for our patients.

Frequently Asked Questions
  1. How big is the Cardiac Marker Testing Market?
    Ans. The Global Cardiac Marker Testing Market size was estimated at USD 5.10 billion in 2023 and expected to reach USD 5.50 billion in 2024.
  2. What is the Cardiac Marker Testing Market growth?
    Ans. The Global Cardiac Marker Testing Market to grow USD 8.69 billion by 2030, at a CAGR of 7.90%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.